Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in metastatic melanoma
NCT00094107Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2004
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of axitinib in melanoma, sponsored by Pfizer. Primary endpoint: Percentage of Participants With Objective Response (OR) up to 147 weeks. Started Dec 2004; status: completed.
02
Drugs
axitinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00094107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094107.